One drug multiple targets: An approach to predict drug efficacies on bacterial strains differing in membrane composition

Rational design methodologies such as quantitative structure activity relationships (QSAR) have conventionally focused on screening through several drugs for their activity against a single target, either a bacterial protein or membrane. Recent concerns in drug design such as the development of drug resistance by membrane adaptation, or the undesirable damage to gut microbiota require a paradigm shift in activity prediction. A complementary approach capable of predicting the activity of a single drug against diverse targets, the diversity arising from bacterial adaptation or a heterogeneous composition with other helpful or harmful bacteria, is needed. As a first predictive step towards this goal, we develop a quantitative model for the activity of daptomycin on Streptococcus aureus strains with different membrane compositions, mainly varying in lysylation. The results of the predictions are good, and within the limits of the scarcely available data, hint at an interaction of daptomycin with the inner membrane. The complementary approach may in principle be extended to estimate the activity against gut bacterial membranes, when systematic data can be curated for training the model.

[1]  L. Danziger,et al.  Daptomycin: a novel cyclic lipopeptide antimicrobial. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  Peer Bork,et al.  Extensive impact of non-antibiotic drugs on human gut bacteria , 2018, Nature.

[3]  P. Fey,et al.  Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. , 2008, Journal of medical microbiology.

[4]  S. Blondelle,et al.  Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. , 2005, Combinatorial chemistry & high throughput screening.

[5]  F. Armstrong,et al.  Current opinion in chemical biology. , 2012, Current opinion in chemical biology.

[6]  Y. Park,et al.  Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates , 2017, Journal of Microbiology.

[7]  Y. Sun,et al.  Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. , 2001, The Journal of biological chemistry.

[8]  H. Shapiro,et al.  Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[9]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[10]  Marc Torrent,et al.  Connecting Peptide Physicochemical and Antimicrobial Properties by a Rational Prediction Model , 2011, PloS one.

[11]  M. Sintchak,et al.  The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. , 2000, Immunopharmacology.

[12]  C. Nast,et al.  Carotenoid-Related Alteration of Cell Membrane Fluidity Impacts Staphylococcus aureus Susceptibility to Host Defense Peptides , 2010, Antimicrobial Agents and Chemotherapy.

[13]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[14]  D. Vanrompay,et al.  Zoonotic Chlamydophila psittaci infections from a clinical perspective. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  C. Nast,et al.  Phenotypic and Genotypic Characterization of Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Strains: Relative Roles of mprF and dlt Operons , 2014, PloS one.

[16]  J. Lakey,et al.  Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. , 1988, Biochemistry.

[17]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[18]  A. Rubio,et al.  Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates. , 2016, The Journal of antimicrobial chemotherapy.

[19]  R. Hancock,et al.  Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. , 2006, Biochimica et biophysica acta.

[20]  C. Nast,et al.  Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[21]  Daniel H. Geschwind,et al.  The Central Nervous System and the Gut Microbiome , 2016, Cell.

[22]  R. Lehrer,et al.  Primate defensins , 2004, Nature Reviews Microbiology.

[23]  Rob Knight,et al.  Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.

[24]  F. Tally,et al.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. , 2005, The Journal of antimicrobial chemotherapy.

[25]  J. Ghuysen,et al.  Multimodular Penicillin-Binding Proteins: An Enigmatic Family of Orthologs and Paralogs , 1998, Microbiology and Molecular Biology Reviews.

[26]  W. Scott,et al.  Effect of divalent cations on the structure of the antibiotic daptomycin , 2008, European Biophysics Journal.

[27]  M. Selsted,et al.  Mammalian defensins in the antimicrobial immune response , 2005, Nature Immunology.

[28]  P. Fey,et al.  Cell Wall Thickening Is Not a Universal Accompaniment of the Daptomycin Nonsusceptibility Phenotype in Staphylococcus aureus: Evidence for Multiple Resistance Mechanisms , 2010, Antimicrobial Agents and Chemotherapy.

[29]  D. Downs,et al.  MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS , 2010, Microbiology and Molecular Biology Reviews.

[30]  J. Davies,et al.  Mechanisms of antibiotic resistance in bacteria. , 1973, Annual review of biochemistry.

[31]  J. Davies,et al.  Origins and Evolution of Antibiotic Resistance , 1996, Microbiology and Molecular Biology Reviews.

[32]  C. Nast,et al.  Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity , 2012, International journal of microbiology.

[33]  C. Nast,et al.  Emergence of Daptomycin Resistance in Daptomycin-Naïve Rabbits with Methicillin-Resistant Staphylococcus aureus Prosthetic Joint Infection Is Associated with Resistance to Host Defense Cationic Peptides and mprF Polymorphisms , 2013, PloS one.

[34]  H. Boucher,et al.  Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  W. Scott,et al.  NMR structural studies of the antibiotic lipopeptide daptomycin in DHPC micelles. , 2007, Biochimica et biophysica acta.

[36]  K. Brogden Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? , 2005, Nature Reviews Microbiology.

[37]  H. Yoneyama,et al.  Antibiotic Resistance in Bacteria and Its Future for Novel Antibiotic Development , 2006, Bioscience, biotechnology, and biochemistry.

[38]  A. Heidari,et al.  Successful treatment of methicillin-resistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure—authors’ response on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium i , 2011 .

[39]  T. Ganz Defensins: antimicrobial peptides of innate immunity , 2003, Nature Reviews Immunology.

[40]  G. Kaatz,et al.  Mechanisms of daptomycin resistance in Staphylococcus aureus. , 2006, International journal of antimicrobial agents.

[41]  R. Bulger,et al.  Antimicrobial Agents and Chemotherapy , 1969, Nature.

[42]  D. Sturdevant,et al.  The antimicrobial peptide‐sensing system aps of Staphylococcus aureus , 2007, Molecular microbiology.

[43]  E. Giralt,et al.  In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  Artem Cherkasov,et al.  Application of 'inductive' QSAR descriptors for quantification of antibacterial activity of cationic polypeptides. , 2004, Molecules.

[45]  R. Hancock,et al.  The role of cationic antimicrobial peptides in innate host defences. , 2000, Trends in microbiology.

[46]  R. H. Baltz Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. , 2009, Current opinion in chemical biology.

[47]  A. Raglio,et al.  dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. , 2014, International journal of antimicrobial agents.

[48]  Michael R. Yeaman,et al.  Mechanisms of Antimicrobial Peptide Action and Resistance , 2003, Pharmacological Reviews.

[49]  J. Schrenzel,et al.  Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding , 2007, Antimicrobial Agents and Chemotherapy.

[50]  David Jung,et al.  Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. , 2008, Chemistry and physics of lipids.